Frequent BCCs linked to blood cancers

Print Friendly, PDF & Email


Woman sunbathing
New research suggests people who develop frequent cases of basal cell carcinoma (BCC) have an increased risk of leukemias, lymphomas, and other cancers. “We discovered that people who develop 6 or more basal cell carcinomas during a 10-year period are about 3 times more likely than the general population to develop other, unrelated... [Read Article]
Print Friendly, PDF & Email

Adult CCSs report financial hardships

Print Friendly, PDF & Email


I-Chan Huang, PhD
Photo from St. Jude
Children’s Research
Hospital/Peter Barta
Health-related financial hardship is common among adult survivors of childhood cancer, according to a study published in the Journal of the National Cancer Institute. Researchers analyzed more than 2800 long-term childhood cancer survivors (CCSs) and found that 65% had financial challenges related to their... [Read Article]
Print Friendly, PDF & Email

FDA approves biosimilar filgrastim

Print Friendly, PDF & Email


Vials of drug
Photo by Bill Branson
The US Food and Drug Administration (FDA) has approved the leukocyte growth factor Nivestym™ (filgrastim-aafi), a biosimilar to Neupogen (filgrastim). Nivestym is approved to treat patients with nonmyeloid malignancies who are receiving myelosuppressive chemotherapy or undergoing bone marrow transplant, acute myeloid leukemia patients receiving induction or consolidation chemotherapy,... [Read Article]
Print Friendly, PDF & Email

Interim PET scans identify HL patients with better outcomes

Print Friendly, PDF & Email


Micrograph showing Hodgkin lymphoma
Interim PET scans can identify a subset of Hodgkin lymphoma (HL) patients with a better outcome suitable for de-escalation treatment after upfront BEACOPP without impairing disease control, according to final results of the AHL2011-LYSA study. BEACOPP, compared to ABVD, improves progression-free survival (PFS) but not overall survival (OS) and is associated... [Read Article]
Print Friendly, PDF & Email

Umbralisib has ‘distinct’ safety profile

Print Friendly, PDF & Email


Micrograph showing CLL
Phase 1 trial results suggest umbralisib, a PI3Kδ/CK1ε inhibitor, can be safe and active in patients with relapsed or refractory B-cell malignancies. Researchers said the safety profile of umbralisib “was distinct from that of other PI3Kδ inhibitors,” as it produced few immune-mediated adverse events (AEs). Umbralisib also produced an objective response... [Read Article]
Print Friendly, PDF & Email

‘Long-term benefits’ with nivolumab in cHL

Print Friendly, PDF & Email


Micrograph showing
Hodgkin lymphoma
Nivolumab can provide “long-term benefits” in patients with relapsed or refractory classical Hodgkin lymphoma (cHL), according to researchers. Extended follow-up of the CheckMate-205 study showed that nearly 70% of patients responded to nivolumab. The median duration of response was 17 months, and the median progression-free survival (PFS) was 15... [Read Article]
Print Friendly, PDF & Email

Art education benefits blood cancer patients

Print Friendly, PDF & Email


Doctor and patient
Photo courtesy of CDC
New research suggests a bedside visual art intervention (BVAI) can reduce pain and anxiety in inpatients with hematologic malignancies, including those undergoing transplant. The BVAI involved an educator teaching patients art technique one-on-one for approximately 30 minutes. After a single session, patients had significant improvements in... [Read Article]
Print Friendly, PDF & Email

FDA approves label update for nivolumab

Print Friendly, PDF & Email


Nivolumab (Opdivo)
Photo from Business Wire
The US Food and Drug Administration (FDA) has updated the label for nivolumab (Opdivo®) to include new dosing and administration information. Nivolumab can now be given at 480 mg infused every 4 weeks for most approved indications, in addition to the previously approved dosing schedule of 240 mg... [Read Article]
Print Friendly, PDF & Email